Tocagen Presents Preliminary Toca 6 Phase 1 Data in Patients with Advanced Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting 2018
As of the data cutoff date of
Data highlights are below. The poster will be placed on
- Cancer-selective expression of the Toca 511 transgene following IV administration was demonstrated in metastatic tumors of 5 patients for whom tissue analyses had been completed, indicating successful delivery of the retroviral replicating vector (RRV).
- Viral RNA, DNA and cytosine deaminase (CD) protein expression was detected in liver metastases from 4 patients with colorectal cancer and retroperitoneal lymph node metastases from 1 patient with pancreas cancer.
- Toca 511 was cleared from blood plasma within 6 weeks following IV administration, indicating the virus is well controlled outside of tumors.
- Toca 511 & Toca FC were well tolerated, supporting the favorable safety profile of the product candidate.
"The preliminary data from the Toca 6 trial represent an important milestone for our RRV platform technology and lead product: for the first time we have demonstrated Toca 511's ability to selectively infect metastases from solid tumors other than glioma following IV delivery, opening potential expansion opportunities for our lead product," said
Additional data from
About Toca 6
Toca 6 is an ongoing Phase 1b study evaluating Toca 511 & Toca FC in patients with advanced solid tumors. The study will evaluate the safety and presence of Toca 511 genes in tumors of patients with widely disseminated disease, immunologic activity in blood and tumor and clinical activity such as tumor response and clinical benefit. More information can be found at www.tocagen.com/toca6 or by searching clinicaltrials.gov using the clinical trial identifier NCT02576665.
About Toca 511 & Toca FC
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our business plans and objectives, timing and success of our clinical trials and planned clinical trials, timing of results from our clinical trials and our plans regarding selection of additional product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost and timing of our product candidate development activities and planned clinical trials; our ability to execute on our strategy; regulatory developments in
View original content with multimedia:http://www.prnewswire.com/news-releases/tocagen-presents-preliminary-toca-6-phase-1-data-in-patients-with-advanced-solid-tumors-at-the-american-association-for-cancer-research-aacr-annual-meeting-2018-300629875.html